RecruitingPhase 1Phase 2NCT07227298

Symbiotic-Lung-20: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Different Anticancer Agents in Advanced Cancers

AN INTERVENTIONAL OPEN-LABEL PHASE 1B/2 STUDY TO EVALUATE THE SAFETY, PHARMACOKINETICS, AND PRELIMINARY EFFICACY OF PF-08634404 IN COMBINATION WITH DIFFERENT ANTICANCER AGENTS IN PARTICIPANTS WITH ADVANCED SOLID TUMORS

Sponsor

Pfizer

Enrollment

162 participants

Start Date

Jan 30, 2026

Study Type

INTERVENTIONAL

Conditions

Non-small Cell Lung Cancer Carcinoma, Non-Small Cell Lung Advanced/Metastatic Non-Small Cell Lung Cancer

Summary

This study is being done to learn more about a new medicine called PF-08634404 and how it works when used with other cancer medicines in people who have advanced solid tumors. An advanced solid tumor is a type of cancer that has spread beyond its original location and cannot be removed by surgery or cured with standard treatments. To join in the study, participants must: * Be 18 years or older * Participants with advanced non-small cell lung cancer (NSCLC), a type of lung cancer that has spread The study will look at: * Whether PF-08634404 is safe to use with other cancer medicines. * What side effects may happen. A side effect is anything the medicine does to your body that is not part of treating your disease. * Whether the combination of PF-08634404 and other cancer medicines can help treat solid tumors. The study has different parts, each testing PF-08634404 with a different cancer medicine: * Part A will test PF-08634404 with a medicine called sigvotatug vedotin. * Part B of the study will look at how well the new medicine PF-08634404 works when used together with another medicine. Participants will receive the study medicines through an intravenous (IV) infusion (injected into the vein) at the study clinic. All treatments will take place at clinical trial sites, where trained medical staff will monitor participants during and after each visit.

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This study tests PF-08634404 in combination with different anticancer agents as a first-line treatment for people with advanced non-small cell lung cancer (NSCLC) that cannot be surgically removed or cured with radiation. **You may be eligible if...** - You have confirmed advanced or metastatic non-small cell lung cancer (stage IIIB/IIIC or IV) - You have not yet received treatment for advanced NSCLC - Your PD-L1 status is known (for certain parts of the study, a positive score ≥ 1% is needed) - You have at least one measurable tumor - Your general health is good (ECOG 0 or 1) **You may NOT be eligible if...** - Your cancer has known driver mutations (EGFR, ALK, ROS1, NTRK, BRAF, MET) - You have had another cancer in the past 3 years - You have active cancer in the brain or spinal cord - You have had an active autoimmune disease requiring treatment in the past 2 years - You have received prior treatment for advanced NSCLC Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

BIOLOGICALPF-08634404

-Concentrate for solution for infusion

BIOLOGICALSigvotatug Vedotin

-Powder for concentrate for solution for infusion. Single use vial

BIOLOGICALCombination Agent 1

-Powder for concentrate for solution for infusion. Single use vial.

Locations(32)

Highlands Oncology Group, PA

Fayetteville, Arkansas, United States

Highlands Oncology Group, PA

Rogers, Arkansas, United States

Highlands Oncology Group, PA

Springdale, Arkansas, United States

Providence Medical Foundation

Fullerton, California, United States

Providence St. Jude Medical Center - Virginia K. Crosson Cancer Center and Infusion Center

Fullerton, California, United States

Providence St. Jude Medical Center

Fullerton, California, United States

Rocky Mountain Cancer Centers, LLP

Denver, Colorado, United States

BRCR Medical Center Inc.

Coral Springs, Florida, United States

Mid Florida Hematology and Oncology Center

Orange City, Florida, United States

BRCR Global - Tamarac

Tamarac, Florida, United States

Oncology Associates of Oregon, P.C.

Eugene, Oregon, United States

Dallas Cancer Specialists

Garland, Texas, United States

Southwest Oncology Associates

Houston, Texas, United States

Lumi Research

Houston, Texas, United States

US Oncology Investigational Products Center (IPC)

Irving, Texas, United States

Voyage Clinical

Sugar Land, Texas, United States

VCU Medical Center Gateway Building